The metabolic process which fuels the growth of many cancers has its origins in normal brain growth finds a new study published in BioMed Central's open access journal Cancer & Metabolism. Using knock-out mice the study shows that interfering with Hexokinase-2 (Hk2), an enzyme integral to glucose metabolism, reduces the aggressiveness of medulloblastoma, the most common malignant brain tumor in children, and allows long term survival of mice.
Most cells only convert glucose to lactate in the absence of oxygen, for example, during a short burst of intensive exercise (anaerobic glycolysis). However rapidly dividing cells, including many cancer cells, convert glucose to lactate even in the presence of oxygen (aerobic glycolysis).
Researchers from the University of North Carolina have found that Hk2 switches on aerobic glycolysis in progenitor cells of the brain and in medulloblastoma. In the absence of Hk2, brain development was disordered. Additionally they found that deleting the Hk2 gene in mice genetically prone to develop medulloblastoma reduced the aggressiveness of the tumors, allowing long-term survival of the mice.
Dr. Timothy Gershon, who led this study, explained, "As long ago as 1924 Otto Warburg hypothesized that cancers use glycolysis to provide energy for growth even in the presence of oxygen. We found that glycolysis in the presence of oxygen is a developmental process that is co-opted in cancer to support malignant growth. We can now think about targeting this process in patients".
Open access publisher BioMed Central is proud to announce the launch of the Cancer & Metabolism . Professor Chi van Dang, co-Editor-in-Chief, commented that "It has become self-evident that metabolism and bioenergetics are regulated by cancer genes. Cancer & Metabolism is launched uniquely to fulfil the needs of a burgeoning field." Professor Michael Pollak, co-Editor-in-Chief, added that "The scope of Cancer & Metabolism will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
BioMed Central: http://www.biomedcentral.com
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
People who suffer from mental health issues also suffer from its stigma. Portraying mental illness as a good thing helps no one
The inventor of a breakthrough DNA test for Down syndrome says the technology can be used to screen people for cancer.The Hong Kong scientist who invented a simple blood test to show pregnant women if their babies have Down syndrome is now testing a similar technology for cancer.
Dr Jeremy Farrar of Wellcome Trust says international community is belatedly taking actions necessary to stem tide of disease
Miniature stomachs gastric organoids will help in study of ulcers and could be used in future to repair patients stomachs
The story of the vaccines development is just one part of a rich and intertwined history of scientific discovery and controversy
A highly sensitive blood test for Ebola exists, so why isn't it being used to test all returning health workers from West Africa? Because the virus isn't in the blood in the first stages of infection.
Drinking beverages enriched with compounds found in cocoa beans improved older adults' performances on a memory test – but there's a catch
A 700-year-old caribou dropping from northern Canada holds surprisingly well-preserved viruses. There's no evidence the viruses are dangerous, but they are scientifically interesting.
The New England Journal of Medicine published an editorial against quarantining people who have worked with Ebola patients in Africa. Renee Montagne speaks with Dr. Lindsey Baden, one of the authors.
Surgeons in Australia say they have performed the first heart transplant using a "dead heart".